Pancreatic cancer cell-derived semaphorin 3A promotes neuron recruitment to accelerate tumor growth and dissemination.
暂无分享,去创建一个
Y. Shan | Ya-li Tsai | Ya-Chin Hou | Yung-Yeh Su | Li-Tzong Chen | Yu-Hsuan Hung | Shih-Han Hsu | Li-Yun Wang | Wen-Chun Hung
[1] M. Fujishiro,et al. The Role of Neural Signaling in the Pancreatic Cancer Microenvironment , 2022, Cancers.
[2] Megumi Watanabe,et al. Semaphorin 3A: A potential target for prevention and treatment of nickel allergy , 2022, Communications Biology.
[3] K. Kuwako,et al. Molecular mechanisms regulating the spatial configuration of neurites. , 2022, Seminars in cell & developmental biology.
[4] A. Maitra,et al. Translational advances in pancreatic ductal adenocarcinoma therapy , 2022, Nature Cancer.
[5] W. Hung,et al. Semaphorin 6C Suppresses Proliferation of Pancreatic Cancer Cells via Inhibition of the AKT/GSK3/β-Catenin/Cyclin D1 Pathway , 2022, International journal of molecular sciences.
[6] Jing Deng,et al. Semaphorin 3A attenuates the hypoxia suppression of osteogenesis in periodontal ligament stem cells. , 2022, Journal of periodontal research.
[7] A. Jemal,et al. Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.
[8] Y. Tien,et al. Distinct Survival Outcomes in Subgroups of Stage III Pancreatic Cancer Patients: Taiwan Cancer Registry and Surveillance, Epidemiology and End Results registry , 2021, Annals of Surgical Oncology.
[9] Kenji Tsuji,et al. Semaporin3A-inhibitor ameliorates renal fibrosis through the regulation of JNK signaling. , 2021, American journal of physiology. Renal physiology.
[10] C. Jiang,et al. Tumor innervation and clinical outcome in pancreatic cancer , 2021, Scientific Reports.
[11] K. Ishido,et al. Roles of the nervous system in pancreatic cancer , 2021, Annals of gastroenterological surgery.
[12] Hua You,et al. Semaphorins as emerging clinical biomarkers and therapeutic targets in cancer , 2021, Theranostics.
[13] A. Koong,et al. Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer , 2020, Clinical Cancer Research.
[14] L. You,et al. Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides? , 2020, Frontiers in Oncology.
[15] M. O'Hara,et al. Challenges and Opportunities for Pancreatic Cancer Immunotherapy. , 2020, Cancer cell.
[16] M. Kano,et al. Influences of Semaphorin 3A Expression on Clinicopathological Features, Human Papillomavirus Status, and Prognosis in Oropharyngeal Carcinoma , 2020, Microorganisms.
[17] Kenji Tsuji,et al. Semaphorin3A-Inhibitor Ameliorates Doxorubicin-Induced Podocyte Injury , 2020, International journal of molecular sciences.
[18] G. Tang,et al. Synthesis of some new acylhydrazone compounds containing the 1,2,4-triazole structure and their neuritogenic activities in Neuro-2a cells , 2020, RSC advances.
[19] J. Peeler,et al. Premature satellite cell activation before injury accelerates myogenesis and disrupts neuromuscular junction maturation in regenerating muscle. , 2020, American journal of physiology. Cell physiology.
[20] Devin P. Sullivan,et al. The human secretome , 2019, Science Signaling.
[21] Othman Soufan,et al. NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis , 2019, Nucleic Acids Res..
[22] H. Okano,et al. Astrocyte-Derived Exosomes Treated With a Semaphorin 3A Inhibitor Enhance Stroke Recovery via Prostaglandin D2 Synthase , 2018, Stroke.
[23] G. Neufeld,et al. Semaphorin-3A inhibits multiple myeloma progression in a mouse model , 2018, Carcinogenesis.
[24] Thinzar M. Lwin,et al. MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model. , 2018, Tissue & cell.
[25] H. Okano,et al. The Semaphorin 3A inhibitor SM-345431 preserves corneal nerve and epithelial integrity in a murine dry eye model , 2017, Scientific Reports.
[26] D. Nam,et al. Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress Glioblastoma Tumor Growth , 2017, Cancer research and treatment : official journal of Korean Cancer Association.
[27] G. Kéri,et al. Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers , 2017, PloS one.
[28] Thinzar M. Lwin,et al. MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX) , 2017, Oncotarget.
[29] E. Bongarzone,et al. SVCT2 Overexpression in Neuroblastoma Cells Induces Cellular Branching that is Associated with ERK Signaling , 2016, Molecular Neurobiology.
[30] D. V. Von Hoff,et al. Blocking Nerve Growth Factor Signaling Reduces the Neural Invasion Potential of Pancreatic Cancer Cells , 2016, PloS one.
[31] Xiaojie Huang,et al. Design and Synthesis of Dimeric Securinine Analogues with Neuritogenic Activities. , 2016, ACS chemical neuroscience.
[32] V. Subramanian,et al. PA6 Stromal Cell Co-Culture Enhances SH-SY5Y and VSC4.1 Neuroblastoma Differentiation to Mature Phenotypes , 2016, PloS one.
[33] B. Pasche,et al. TGFβ Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis. , 2016, Cancer research.
[34] Claude Chelala,et al. A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma , 2014, Genome Medicine.
[35] Chirayu Pankaj Goswami,et al. PROGgeneV2: enhancements on the existing database , 2014, BMC Cancer.
[36] S. Offermanns,et al. Semaphorins and plexins as therapeutic targets , 2014, Nature Reviews Drug Discovery.
[37] Joon-Oh Park,et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. , 2014, European journal of cancer.
[38] E. Vakiani,et al. GFRα1 released by nerves enhances cancer cell perineural invasion through GDNF-RET signaling , 2014, Proceedings of the National Academy of Sciences.
[39] S. Leach,et al. Sympathetic innervation during development is necessary for pancreatic islet architecture and functional maturation. , 2013, Cell reports.
[40] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[41] Rashmi Chandra,et al. Neurohormonal regulation of pancreatic secretion , 2012, Current opinion in gastroenterology.
[42] L. Zentilin,et al. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. , 2012, The Journal of clinical investigation.
[43] S. McGrath-Morrow,et al. Semaphorin 3A Contributes to Distal Pulmonary Epithelial Cell Differentiation and Lung Morphogenesis , 2011, PloS one.
[44] P. Pasricha,et al. Substance P and calcitonin gene related peptide mediate pain in chronic pancreatitis and their expression is driven by nerve growth factor. , 2011, JOP : Journal of the pancreas.
[45] Wa Shen,et al. Semaphorin3a regulates endothelial cell number and podocyte differentiation during glomerular development , 2009, Development.
[46] L. Zentilin,et al. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. , 2009, The Journal of clinical investigation.
[47] H. Friess,et al. Association of axon guidance factor Semaphorin 3A with poor outcome in pancreatic cancer , 2007, International journal of cancer.
[48] A. Kolodkin,et al. Semaphorin regulation of cellular morphology. , 2007, Annual review of cell and developmental biology.
[49] H. Friess,et al. Nerve growth factor and enhancement of proliferation, invasion, and tumorigenicity of pancreatic cancer cells , 2002, Molecular carcinogenesis.
[50] M. Dickens,et al. Dual Roles for c-Jun N-Terminal Kinase in Developmental and Stress Responses in Cerebellar Granule Neurons , 2000, The Journal of Neuroscience.
[51] B. Ruggeri,et al. Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: Expression patterns and effects on In vitro invasive behavior , 1999, International journal of cancer.
[52] M. Lai,et al. Semaphorin 4C promotes motility and immunosuppressive activity of cancer cells via CRMP3 and PD-L1. , 2022, American journal of cancer research.
[53] H. Friess,et al. Pancreatic neuropathy and neuropathic pain--a comprehensive pathomorphological study of 546 cases. , 2009, Gastroenterology.